Effect of Magnesium Sulfate Infusion Rate on Magnesium Retention in Critically Ill Patients
Primary Purpose
Primary Hypomagnesemia (Disorder)
Status
Terminated
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Magnesium Sulfate
Sponsored by
About this trial
This is an interventional treatment trial for Primary Hypomagnesemia (Disorder) focused on measuring hypomagnesemia, magnesium, magnesium sulfate
Eligibility Criteria
Inclusion Criteria:
Medicine ICU service patients
- > 18 years old with
- hypomagnesemia defined by a serum magnesium level < 2 mg/dL and the clinical decision by the rounding team to replace with parenteral magnesium sulfate
- must have an available IV line for magnesium infusion that may be used for up to 8 hours
- must have a Foley catheter
Exclusion Criteria:
- renal dysfunction defined by an estimated creatinine clearance (CrCl) < 30 mL/min or have had an average of < 0.5 mL/kg/hr of urine output over the previous 12 hours before the magnesium infusion is to begin
- Subjects must not have received a loop diuretic within the 12 hours prior to magnesium replacement and will further be excluded if they receive these medications during the magnesium replacement and urine collection time period
- Subjects with ostomies or acute diarrhea will be excluded due to the possibility of high gastrointestinal magnesium loss
- Subjects will be excluded if they have a physician order for magnesium sulfate to be infused over a specified time period
- If subjects are expected to be moved out of the ICU within the next 24 hours, they will not be considered for randomization due to potential lack of appropriate urine magnesium collection and follow up
- Each subject may only be enrolled in the study for one occurrence of hypomagnesemia
Sites / Locations
- Charleston Area Medical Center
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Experimental
Arm Label
Magnesium 8 grams over 4 hours
Magnesium 8 grams over 8 hours
Arm Description
Outcomes
Primary Outcome Measures
Amount of urinary excretion of magnesium after an 8g magnesium sulfate infusion delivered over 4 hours versus 8 hours.
Secondary Outcome Measures
Mean change in the serum magnesium level after an 8 gm magnesium sulfate infusion delivered over 4 hours and 8 hours
Full Information
NCT ID
NCT01426165
First Posted
August 24, 2011
Last Updated
January 31, 2014
Sponsor
CAMC Health System
Collaborators
Sarah & Pauline Maier Foundation, Inc.
1. Study Identification
Unique Protocol Identification Number
NCT01426165
Brief Title
Effect of Magnesium Sulfate Infusion Rate on Magnesium Retention in Critically Ill Patients
Official Title
Effect of Magnesium Sulfate Infusion Rate on Magnesium Retention in Critically Ill Patients
Study Type
Interventional
2. Study Status
Record Verification Date
January 2014
Overall Recruitment Status
Terminated
Why Stopped
Issues with recruitment. PI decided to terminate study
Study Start Date
April 2011 (undefined)
Primary Completion Date
April 2012 (Actual)
Study Completion Date
December 2012 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
CAMC Health System
Collaborators
Sarah & Pauline Maier Foundation, Inc.
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
Hypomagnesemia (low magnesium) is an electrolyte imbalance commonly found in up to 65% of critically ill patients. Possible consequences of hypomagnesemia include neuromuscular and neurologic dysfunction, heart arrhythmias, and alterations in other electrolytes. Data has shown that critically ill patients with hypomagnesemia have a significantly higher mortality rate than patients with a normal magnesium level. The most simple and commonly used test to diagnose hypomagnesemia is a serum magnesium level. Based on the magnesium level and symptoms of hypomagnesemia, patients may be replaced with either oral or intravenous (IV) magnesium. When replacing magnesium via the IV route, approximately half of the dose is retained by the body while the remainder is excreted in the urine. The low retention rate is due to the slow uptake of magnesium by cells and decreased magnesium reabsorption by the kidneys in response to the delivery of a large concentration of magnesium. The purpose of this study is to determine whether an eight hour compared to a four hour infusion of IV magnesium sulfate results in a greater retention of the magnesium dose.
Detailed Description
Hypomagnesemia is a common electrolyte disturbance that affects up to 65% of intensive care unit (ICU) patients with normal renal function. Causes of hypomagnesemia are attributed to either gastrointestinal (secretory loss, impaired absorption or reabsorption, acute pancreatitis) or renal losses (alcohol, hypercalcemia, volume expansion, loop or thiazide diuretics, nephrotoxic medications, renal tubular dysfunction, inborn disorders). Consequences of magnesium deficiency are not benign and may include neuromuscular and neurologic dysfunction, cardiac arrhythmias and concomitant electrolyte abnormalities including hypokalemia and hypocalcemia. Hypomagnesemia has been associated with a significantly greater mortality rate in critically ill medical patients compared to normomagnesemic patients. In a study conducted by Rubeiz et al, 46% (17/37) of hypomagnesemic patients in the medical ICU died compared to 25% (37/147) of normomagnesemic patients (p < 0.05).
It can be difficult to assess patients for hypomagnesemia because of the unreliable relationship between serum and tissue magnesium levels. Approximately 1% of total body magnesium is found in the extracellular fluid while the remaining 99% is distributed among the bones, muscles, and soft tissues. Approximately 60% of serum magnesium is free ions; 33% is bound to proteins and 7% is complexed with anions. The most simple and commonly used test to diagnose hypomagnesemia is the total serum magnesium level which reflects free magnesium along with complexed and protein bound magnesium. The serum magnesium level, however, is not always accurate at detecting magnesium deficiency. Patients may appear to be normomagnesemic based on their serum magnesium level, yet have an underlying magnesium deficiency. Normal serum magnesium levels vary by laboratory. The normal range of values at Charleston Area Medical Center (CAMC) is 1.6-2.6 mg/dL.
Magnesium replacement depends on the clinical situation and manifestations. In critical conditions such as pre-eclampsia, arrhythmias, and tetany, large doses of IV magnesium are rapidly bolused and often followed by a continuous IV infusion. In asymptomatic patients, magnesium may be replaced by the oral or IV route depending on the clinical situation. The dose required to return patients to the normal magnesium range is variable and replacement may take several doses. Serum magnesium levels are primarily controlled by glomerular filtration and tubular reabsorption at the sites of the Loop of Henle and distal tubule. When faced with an increased filtered load of magnesium, the kidney is capable of increasing its excretion rate. Following intravenous (IV) administration, cellular magnesium uptake is slow and approximately 50% or more of the infused dose is lost due to increased excretion by the kidneys and decreased tubular reabsorption.
The investigators current practice in the Medical and Neuroscience ICUs at CAMC General Hospital is to order 8g of magnesium sulfate for replacement in patients with hypomagnesemia. When IV magnesium sulfate is ordered the pharmacy automatically sets the rate to run at 2g per hour unless otherwise specified. Often times the physician will specify for 8g to be infused over eight hours. The basis of using an extended infusion is that a slower magnesium infusion rate may increase magnesium retention by allowing a longer period of time for magnesium uptake by cells and by decreasing the magnesium load delivered to the kidneys at any given time. As far as the investigators are aware, there have been no studies completed to date that assess the rate of IV magnesium infusion on the magnesium retention rate.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Primary Hypomagnesemia (Disorder)
Keywords
hypomagnesemia, magnesium, magnesium sulfate
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
5 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Magnesium 8 grams over 4 hours
Arm Type
Experimental
Arm Title
Magnesium 8 grams over 8 hours
Arm Type
Experimental
Intervention Type
Drug
Intervention Name(s)
Magnesium Sulfate
Other Intervention Name(s)
magnesium
Intervention Description
8 grams over 4 or 8 hours depending on randomization
Primary Outcome Measure Information:
Title
Amount of urinary excretion of magnesium after an 8g magnesium sulfate infusion delivered over 4 hours versus 8 hours.
Time Frame
24 hours
Secondary Outcome Measure Information:
Title
Mean change in the serum magnesium level after an 8 gm magnesium sulfate infusion delivered over 4 hours and 8 hours
Time Frame
24 hours
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Medicine ICU service patients
> 18 years old with
hypomagnesemia defined by a serum magnesium level < 2 mg/dL and the clinical decision by the rounding team to replace with parenteral magnesium sulfate
must have an available IV line for magnesium infusion that may be used for up to 8 hours
must have a Foley catheter
Exclusion Criteria:
renal dysfunction defined by an estimated creatinine clearance (CrCl) < 30 mL/min or have had an average of < 0.5 mL/kg/hr of urine output over the previous 12 hours before the magnesium infusion is to begin
Subjects must not have received a loop diuretic within the 12 hours prior to magnesium replacement and will further be excluded if they receive these medications during the magnesium replacement and urine collection time period
Subjects with ostomies or acute diarrhea will be excluded due to the possibility of high gastrointestinal magnesium loss
Subjects will be excluded if they have a physician order for magnesium sulfate to be infused over a specified time period
If subjects are expected to be moved out of the ICU within the next 24 hours, they will not be considered for randomization due to potential lack of appropriate urine magnesium collection and follow up
Each subject may only be enrolled in the study for one occurrence of hypomagnesemia
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jack L DePriest, MD
Organizational Affiliation
WVU School of Medicine/Charleston Division
Official's Role
Principal Investigator
Facility Information:
Facility Name
Charleston Area Medical Center
City
Charleston
State/Province
West Virginia
ZIP/Postal Code
25301
Country
United States
12. IPD Sharing Statement
Citations:
PubMed Identifier
3965244
Citation
Ryzen E, Wagers PW, Singer FR, Rude RK. Magnesium deficiency in a medical ICU population. Crit Care Med. 1985 Jan;13(1):19-21. doi: 10.1097/00003246-198501000-00006.
Results Reference
background
PubMed Identifier
17065651
Citation
Epstein M, McGrath S, Law F. Proton-pump inhibitors and hypomagnesemic hypoparathyroidism. N Engl J Med. 2006 Oct 26;355(17):1834-6. doi: 10.1056/NEJMc066308. No abstract available.
Results Reference
background
PubMed Identifier
19920278
Citation
Broeren MA, Geerdink EA, Vader HL, van den Wall Bake AW. Hypomagnesemia induced by several proton-pump inhibitors. Ann Intern Med. 2009 Nov 17;151(10):755-6. doi: 10.7326/0003-4819-151-10-200911170-00016. No abstract available. Erratum In: Ann Intern Med. 2010 Feb 16;152(4):268.
Results Reference
background
PubMed Identifier
7977315
Citation
al-Ghamdi SM, Cameron EC, Sutton RA. Magnesium deficiency: pathophysiologic and clinical overview. Am J Kidney Dis. 1994 Nov;24(5):737-52. doi: 10.1016/s0272-6386(12)80667-6.
Results Reference
background
PubMed Identifier
8428470
Citation
Rubeiz GJ, Thill-Baharozian M, Hardie D, Carlson RW. Association of hypomagnesemia and mortality in acutely ill medical patients. Crit Care Med. 1993 Feb;21(2):203-9. doi: 10.1097/00003246-199302000-00010.
Results Reference
background
PubMed Identifier
8304365
Citation
McLean RM. Magnesium and its therapeutic uses: a review. Am J Med. 1994 Jan;96(1):63-76. doi: 10.1016/0002-9343(94)90117-1.
Results Reference
background
PubMed Identifier
2914469
Citation
Zaloga GP. Interpretation of the serum magnesium level. Chest. 1989 Feb;95(2):257-8. doi: 10.1378/chest.95.2.257. No abstract available.
Results Reference
background
PubMed Identifier
13575537
Citation
CHESLEY LC, TEPPER I. Some effects of magnesium loading upon renal excretion of magnesium and certain other electrolytes. J Clin Invest. 1958 Oct;37(10):1362-72. doi: 10.1172/JCI103726. No abstract available.
Results Reference
background
PubMed Identifier
13796804
Citation
BARKER ES, ELKINTON JR, CLARK JK. Studies of the renal excretion of magnesium in man. J Clin Invest. 1959 Oct;38(10 Pt 1-2):1733-45. doi: 10.1172/JCI103952. No abstract available.
Results Reference
background
PubMed Identifier
1244564
Citation
Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31-41. doi: 10.1159/000180580.
Results Reference
background
PubMed Identifier
10405219
Citation
Agus ZS. Hypomagnesemia. J Am Soc Nephrol. 1999 Jul;10(7):1616-22. doi: 10.1681/ASN.V1071616. No abstract available.
Results Reference
background
Learn more about this trial
Effect of Magnesium Sulfate Infusion Rate on Magnesium Retention in Critically Ill Patients
We'll reach out to this number within 24 hrs